Ann: Dimerix and Taiba enter into License Agreement for DMX-200, page-111

"DJ Dimerix's Middle East Licensing Deal Signals More Agreements to Come -- Market Talk"

"Dimerix's licensing deal with UAE-based pharmaceutical group Taiba for its DMX-200 treatment of focal segmental glomerulosclerosis, a rare kidney disease, in the Middle East is a positive surprise to Euroz Hartleys. That's because the bank's forecasts for DMX-200 were based on sales in the U.S. and Europe. Dimerix will receive A$500,000 upfront from Taiba, up to A$120 million in potential milestone payments, and tiered royalties starting at 30% of net sales. "We are now more confident on Dimerix executing further licensing agreements, with major regions such as the U.S. and China still to be licensed," analyst Seth Lizee says. "Dimerix has noted it continues to negotiate with potential licensees, including on various non-binding term sheets received." ([email protected]; @dwinningWSJ)"